mTORC1 activity is supported by spatial association with focal adhesions

Abstract The mammalian target of rapamycin complex 1 (mTORC1) integrates mitogenic and stress signals to control growth and metabolism. Activation of mTORC1 by amino acids and growth factors involves recruitment of the complex to the lysosomal membrane and is further supported by lysosome distributi...

Full description

Saved in:
Bibliographic Details
Published inbioRxiv
Main Authors Rabanal-Ruiz, Yoana, Byron, Adam, Wirth, Alexander, Madsen, Ralitsa, Sedlackova, Lucia, Hewitt, Graeme, Nelson, Glyn, Stingele, Julian, Wills, Jimi C, Zhang, Tong, Zeug, André, Fässler, Reinhard, Vanhaesebroeck, Bart, Oliver Dk Maddocks, Ponimaskin, Evgeni, Carroll, Bernadette, Korolchuk, Viktor I
Format Paper
LanguageEnglish
Published Cold Spring Harbor Cold Spring Harbor Laboratory Press 20.11.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract The mammalian target of rapamycin complex 1 (mTORC1) integrates mitogenic and stress signals to control growth and metabolism. Activation of mTORC1 by amino acids and growth factors involves recruitment of the complex to the lysosomal membrane and is further supported by lysosome distribution to the cell periphery1–4. Here we show that translocation of lysosomes towards the cell periphery brings mTORC1 into proximity with focal adhesions (FAs). We demonstrate that FAs constitute discrete plasma membrane hubs mediating growth factor signaling and amino acid input into the cell. FAs, as well as the translocation of lysosome-bound mTORC1 to their vicinity, are necessary for both peripheral and intracellular mTORC1 activity. Conversely, lysosomal distribution to the cell periphery is dispensable for the activation of mTORC1 constitutively targeted to FAs. This study advances our understanding of spatial mTORC1 regulation by demonstrating that the localization of mTORC1 to FAs is both necessary and sufficient for its activation by growth-promoting stimuli. Competing Interest Statement B.V. is a consultant for Karus Therapeutics (Oxford, UK), iOnctura (Geneva, Switzerland) and Venthera (Palo Alto, US) and has received speaker fees from Gilead (Foster City, US). The other authors declare no competing financial interests.
DOI:10.1101/2020.11.20.391888